ClinicalTrials.gg
Not yet recruitingNCT06890182Updated Mar 21, 2025

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

A Phase 2 interventional study of Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed in Non-small Cell Lung Cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung — 31 open to participants now, 34 under way, 5 of them phase 3. aflutinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
33rd of 41
31 · median 60
Started
2025
with 6 others
Phase 2
26 of 41
22 open now
Primary completion
2026-12
later than 14 of 33 live
Registered
27th of 41
by date
Lead sponsor
3 of 41
Tianjin Medical University Cancer Institute and Hospital

Among the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, this one is the 33rd largest by planned enrollment, is one of 7 that started in 2025, is one of 26 in phase 2, reaches primary completion later than 14 of the 33 other live ones, and was the 27th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

31 of the 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About aflutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing aflutinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a phase II study aimed to assess the efficacy and safety of firmonertinib combined with carboplatin/cisplatin and pemetrexed as neoadjuvant therapy in stage II-IIIB resectable NSCLC patients.

Read the detailed description

In this open-label, single-arm, phase 2 study, 31 eligible patients with EGFR mutated stage IIIA-IIIB resectable NSCLC will be recruited to receive firmonertinib for 12 weeks combined with carboplatin/cisplatin and pemetrexed for 4 cycles (21 d/cycle) as neoadjuvant therapy before radical surgery. Radiological and pathological evaluations will be performed before and after the neoadjuvant therapy to assess the efficacy of treatment. Adverse events during neoadjuvant therapy, disease and survival status will also be collected in the study.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide prior to any study specific procedures
  2. at least 18 years of age
  3. Histology or cytology diagnose of non-small cell lung cancer within 60 days
  4. PS of 0 to 1 at screening with no deterioration in the previous 2 weeks
  5. Stage II-IIIB NSCLC that is expected to be resectable, as assessed by the investigator (8 thUICCTNM staging),
  6. According to 1.1, patients have at least one measureable tumor lesion (The longest axis ≥10mm)
  7. EGFR mutation positive (exon 19 deletions or exon 21 L858R, with or without other EGFR mutations)
  8. Without prior anti-tumor treatment
  9. Withe adequate organ function of hematology, liver and kidney
  10. Using adequate and effective , Male patients should be use condoms; women should refrain from breastfeeding and have a negative pregnancy test prior to the first administration of the study drug if within during child-bearing age

Exclusion criteria

Exclusion Criteria:

  1. Dual or multiple primary NSCLC
  2. Any prior anti-tumor treatment
  3. With history of other except for radical resected tumors without recurrence for 5 years or more
  4. Diseases or clinical states with severe abnormalities of gastrointestinal function that may interfere with the ingestion, transit, or absorption of the study drug.e.g., inability to take medication orally, uncontrolled nausea and vomiting
  5. With severe or uncontrolled systemic disease such as uncontrolled hypertention, diabetes mellitus, chronic heart failure, unstable angina, myocardial infarction within 1 year, active hemorrhage, active // or other infections requiring infusion treatment
  6. Laboratory tests indicate insufficient bone marrow reserve or organ reserve
  7. Women with pregnancy or breastfeeding
  8. Patients with known or suspected drug allergies, or other
  9. Other conditions that, in the opinion of the investigator, make participation in this trial inappropriate
  10. Patients who are currently or previously enrolled in any other anti-tumor clinical study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed

    furmonertinib 80mg/d for 12 weeks and carboplatin AUC5 d1 iv / cisplatin 75mg/m2 d1 iv+ pemetrexed 500mg/m2 d1 iv at 21 day cycles for 4 cycles

    Drug: Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Major pathological response rate (MPR)

    Proportion of resected specimens with ≤10% residual tumor cells assessed by surgical specimen pathology

    Time frame: Approximately 24 weeks following the first dose of study drug

Secondary outcomes

  1. Pathological Complete Response Rate(pCR)

    The proportion of patients with pathological response rate in the resected tumor.

    Time frame: Approximately 24 weeks following the first dose of study drug

  2. Objective Response Rate (ORR)

    According to RECIST 1.1 criteria, after 8 weeks of neoadjuvant therapy CT scans scans assessed the proportion of patients in partial and complete remission.

    Time frame: Approximately 8 weeks following the first dose of study drug

  3. Rate of R0 Resection

    The proportion of patients with R0 resection.

    Time frame: Approximately 16 weeks following the first dose of study drug

  4. Pathological downstaging of lymph node rate

    The proportion of patients with pathological downstaging of lymph node rate

    Time frame: Approximately 16 weeks following the first dose of study drug

  5. Incidence of adverse events (AE)

    The number of patients with adverse events and the severity according to CTCAE v5.0

    Time frame: Approximately 12 weeks following the first dose of study drug

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Dec 2026, 21 months later.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 21 months is below that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2025
First posted
Mar 21, 2025
StartEst.
Mar 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06890182
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Mar 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 21, 2025

Study contacts

Zhansheng Jiang
Contact
18526812877@163.com
13512035574
Zhansheng Jiang
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aflutinib · Carboplatin · Cisplatin · Pemetrexed

Start the discussion